Business Context and Reporting Period
This Form 6-K filing by Evaxion Biotech A/S, a foreign private issuer, was submitted on April 4, 2025. The report serves to incorporate by reference the convening notice and proxy form for the Company's Annual General Meeting (AGM) scheduled for April 30, 2025, at 14:00 CEST.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural filing regarding corporate governance and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are reported in this filing. The document focuses solely on the administrative logistics of the upcoming Annual General Meeting.
Guidance, Outlook, and Risks
Management commentary, financial guidance, outlook, risks, contingencies, and unusual items are not addressed in this specific filing. The content is limited to the notice of the AGM and the associated proxy materials.
Key Facts for Investors
- Event: Annual General Meeting of Evaxion Biotech A/S.
- Date and Time: April 30, 2025, at 14:00 CEST.
- Documents Included: Notice of the AGM (Exhibit 99.1) and Proxy Form (Exhibit 99.2).
- Signatory: Christian Kanstrup, Chief Executive Officer.
- Financial Data: None provided in this filing.